CORRECTION OPEN

Correction To: Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss

Chen Kan, Jiazhao Yang, Haitao Fan, Yuanjuan Dai, Xingxing Wang, Rui Chen, Jia Liu, Xiangyue Meng, Wei Wang, Guiling Li, Jiao Zhou, Ya Zhang, Wanbo Zhu, Shiyuan Fang, Haiming Wei, Hong Zheng, Siying Wang and Fang Ni

Bone Research (2022)10:64 ; https://doi.org/10.1038/s41413-022-00238-5

Correction to: *Bone Research* https://doi.org/10.1038/s41413-022-00232-x, published online 27 October 2022

Following publication of this article[1], it is noticed that a sentence "FetA was characterized as a decoy receptor of transforming growth factor beta (TGF-β)/BMP, suggesting that FetA could be useful to inhibit and/or prevent TGF-β/BMP-induced diseases, including heterotopic ossification[61,62,63,64]." needs to be inserted in the section DISCUSSION. References 61–64 are also added.

In addition, the reference number "2019YFA0801801" should be changed to "2019YFA0801800" in the section ACKNOWLEDGEMENTS.

The original article[1] was updated.

REFERENCE

1. Kan, C. et al. Fetuin-A is an immunomodulator and a potential therapeutic option in BMP4-dependent heterotopic ossification and associated bone mass loss. *Bone Res.* **10**, 62 (2022).

Published online: 15 November 2022